Supernus Pharmaceuticals, Inc. (0LB2.L)

29,01 -0,57 (-1,91%) Al 03:11PM BST. Mercato aperto.

Supernus Pharmaceuticals, Inc.

9715 Key West Avenue
Rockville, MD 20850
United States
301 838 2500
https://www.supernus.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 612

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Jack A. Khattar	Founder, Pres, CEO, Sec. & Director	1,63M	10,79M	1961
Mr. Timothy C. Dec	Sr. VP & CFO	635,43k	N/D	1959
Dr. Padmanabh P. Bhatt Ph.D.	Chief Scientific Officer & Sr. VP of Intellectual Property	594,14k	334,6k	1957
Mr. Frank Mottola	Sr. VP of Quality, GMP Operations & Information Technology	490,87k	N/D	1972
Dr. Jonathan Rubin M.D., MBA	Sr. VP of R&D and Chief Medical Officer	594,65k	N/D	1961
Mr. Kevin T. Anderson	Compliance Officer	N/D	N/D	1962
Dr. Todd Horich M.B.A., Ph.D.	Sr. VP of Marketing & Market Access	N/D	N/D	N/D
Mr. Taylor Raiford	Sr. VP of Sales	N/D	N/D	N/D
Dr. Bryan A. Roecklein Ph.D.	Sr. VP of Corp. Devel.	N/D	N/D	N/D
Ms. Tami T. Martin Esq., R.N.	Sr. VP of Regulatory Affairs	N/D	N/D	1955

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Governance aziendale

L'ISS Governance QualityScore di Supernus Pharmaceuticals, Inc. al 1 settembre 2023 è 6. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 4; diritti degli azionisti: 7; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.